Background: Erythropoietin (rHuEPO) therapy improves the success of autologous blood (AB) donation programs before elective surgery. We aimed at evaluating iron absorption during an AB donation program with or without rHuEPO.
Inclusion of patients who are planned for elective surgery in autologous blood (AB) donation programs represents an alternative to allogeneic blood transfusions. [2] [3] One unit of AB can be donated every 72 hours provided that the hematocrit (Hct) remains higher than 33%. The main limitations to the predonation of the required amount of blood are ironrestricted erythropoiesis [4] [5] and an unadapted endogenous erythropoietin (EPO) response to serial phlebotomy. 6 While basal red blood cell (RBC) production in response to phlebotomyinduced anemia is doubled, 7 iron availability becomes the limiting factor for efficient erythropoiesis. Conversely, such iron-restricted erythropoiesis is not encountered in patients with genetic hemochromatosis (7-fold basal RBC production) 8 or in patients receiving intravenous iron supplementation (3.5 to 4.5 fold basal RBC production). 9 Previous studies have shown that storage, circulating and total body iron were lower in patients unable to donate the required amount of blood even with an oral iron supplementation of 375 mg iron sulfate three times a day. 7 These data suggest that oral iron absorption could be insufficient to meet the demand created by increased erythropoietic activity. However, a randomized controlled study comparing the efficacy of oral (100 mg Fe either of the applied regimens. 10 The relationship between the degree of anemia and log(endogenous EPO levels) is known to be linear. a consequence, the red cell content of each AB unit collected is 20% lower than in allogeneic blood units. 13 The use of recombinant human erythropoietin (rHuEPO) in AB donation programs results from these observations. A meta-analysis examining the effect of rHuEPO therapy on the capacity of patients to donate autologous blood before elective surgery concluded that the odds ratio for the proportion of patients transfused with allogeneic blood was 0.42 (CI 0.28-0.62) for orthopedic surgery and 0.25 (CI 0.08-0.82) for cardiac surgery. 14 Goodnough et al. 15 , in a prospective, randomized, double-blind study, have shown that patients treated with 600 U/kg rHuEPO TIW for 21 days of AB donation (6 units collected) were able to procure more units and a higher RBC volume than patients receiving placebo. The hematocrit values and the reticulocyte response were also significantly higher in the rHuEPO group by the third visit. Nevertheless, the success of AB collection remained dependent on the initial mobilizable circulating iron. However, whereas the role of rHuEPO is to increase mobilizable circulating iron, 15 the source of this iron, either storage iron or orally absorbed iron, has not been demonstrated.
The current study was performed to examine how oral iron supplementation was useful to support erythropoiesis when stimulated by rHuEPO during an AB donation program. We aimed at identifying the source of iron used for RBC production under rHuEPO stimulation and at estimating the total amount of excess iron absorbed during that period. 
Patients and methods

Patients
Thirty-two patients scheduled for elective orthopedic (23 total hip arthroplasties and 8 total knee arthroplasties) or cardio-vascular surgery (I aortic valve replacement) were included.
They were randomly assigned to three groups. Group 1 was treated with placebo (N = 10). In group 2, patients were treated with 300 UI/kg rHuEPO on1st, 2 nd and 3 rd donation visits (days 0, 4 and 7) (N = 11). Patients in group 3 received a rHuEPO dose of 600 UI/kg at the same interval than group 2 (N = 11). The patients included in this study were part of a cohort of patients included in a milticentric trial to evaluate the safety and efficacy of epoietin alpha in autologous blood donation program. This study is a sub-analysis concerning iron metabolism in this field. All the patients from our center included in the multicentric study were included in the present study. The characteristics of the population are shown in table 1.
Randomization resulted in patients similar for age, sex, baseline Hb or Hct level and baseline iron status. All patients signed an informed consent form before inclusion into the study and the protocol was approved by the Ethics Committee of the University of Liège.
Study design
Visits were scheduled on days 0, 4, 7, 11 and 14. At each visit, one unit (450 mL) of AB was collected as long as Hct remained > 33%, with a maximum of 5 AB units. Placebo or rHuEPO was administered subcutaneously, on days 0, 4, 7. All patients received 200 mg Fe + as oral ferrous sulfate and 5 mg folate, orally, from day 0 to discharge. Surgery was scheduled on day 21 . Blood samples were drawn at each visit, on the evening of the day of surgery, on postoperative day +3 and on the day of discharge. Storage iron (SI; mg) = 400 + (ln ferritin -ln 12). 16 Mobilizable circulating iron (MCI; mg) = BV x ((Hct-34)/100). 15, 17 Total mobilizable iron (TMI; mg) = SI + MCI. 
Laboratory tests
Results
Blood donation (Table 2) There was a dose-response difference in the number of units that was collected etween groups. The target of 5 units/patient was achieved in 91% of patients in group 3 vs 82% in group 2 and 72% in group 1. The number of units collected in groups 1, 2 and 3 were 3.6 ± 0.8, 4.1 ± 0.5 and 4.6 ± 0.5 per patient, respectively. Compared to group 1, the difference was significant (p < 0.01) with group 3 receiving 600 UI/kg rHuEPO, and was at the limit of significance (p = 0.058) with group 2. RBC volume/unit donated was better in group 3 compared to groups 2 (NS) and 1 (p < 0.05) ( Figure 1 ). Hence, the total RBC volume donated in group 3 was about 50% higher than in group 1 ( Table 2) .
Erythropoiesis
At baseline, the endogenous EPO level of group 3 was significantly higher compared to the placebo group but within the normal range. The reticulocyte count, at baseline, was higher in group 2 when compared with the 2 other groups but within the normal range.
Cumulative RBC production was significantly increased by rHuEPO therapy in a dosedependent manner ( Figure 2 ). The difference became significant by visit 3 (day 7). Total Hb production was also significantly different (group 1: 105.1 ± 44.5 gr, group 2: 151.7 ± 41.1 gr, group 3: 191.5 ± 44.4 gr Hb; p = 0.02 (group 2 vs group 1), p < 0.001 (group 3 vs group 1), p = 0.009 (group 3 vs group 2)). As shown by soluble transferrin receptors (sTfR) levels, erythropoietic activity remained stable throughout the study in group 1 but was strongly stimulated in patients receiving rHuEPO (74% increase in group 2 and 117% increase in group 3) (Figure 3 ). After cessation of rHuEPO therapy, erythropoietic activity progressively returned to baseline before surgery when it was quite similar in the 3 groups. Reticulocytes peaked at visit 4 in patients receiving rHuEPO (p < 0.001 for group 2 and 3 vs group 1). Serum EPO peaked at visit 3 in group 3, 4 days earlier than the peak of reticulocytes and was significantly higher than in group 1 (p = 0.005) or group 2 (p = 0.048).
Despite higher amounts of blood donated under rHuEPO therapy, and because of differences in RBC and Hb production, Hb (group 1: 11.5 ± 0.8; group 2: 12.0 ± 0.9; group 3: 11.9 ± 1.0 g/dL; NS) and Hct values before surgery remained similar in the three groups (Figure 3 ).
Blood losses and transfusions
Blood losses during surgery were similar among the 3 groups (group 1: 1,784 ± 902; group 2:
1,427 ± 921; group 3: 1,414 ± 595 mL; NS). All patients required transfusions during or after surgery. There were no difference in the total number of units transfused (group 1: 4.0 ± 1.6; group 2: 3.5 ± 0.8; group 3: 3.8 ± 1.6; NS) . However, because of differences in the number of units collected, allogeneic transfusions were necessary for 1 patient in group 3 (5% of rHuEPO-treated patients) and 4 in group 1 (40% of the placebo group) (p = 0.01).
Iron metabolism
Data concerning iron metabolism are summarized in table 3. Ferritin, serum iron and transferin saturation decreased significantly during the donation period. As a consequence, calculated storage iron (SI) decreased. Mobilizable circulating iron (MCI) also decreased following phlebotomies, whereas total iron (TI) increased from baseline to pre-surgery since it integrates both body iron (storage iron and RBC iron) and donated iron. Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 increase in the number of units than can be donated. 15, [18] [19] RHuEPO therapy further increases RBC production. A previous study showed that it leads to RBC production equivalent to 5 units of blood during the donation period, whereas a placebo group produced only 3 units. 20 This stimulation of erythropoiesis also allows the red cell mass to return to normal before surgery in patients treated with rHuEPO. 21 In addition to confirming the success rate of AB donation with rHuEPO, our study has shown that, through faster and larger increase in RBC production, the RBC volume of a single unit remained far more stable throughout successive phlebotomies with rHuEPO compared to placebo. Therefore, the RBC volume in AB units collected remained nearly equivalent to that of allogeneic donations in the group treated with 600 UI/kg rHuEPO. Hence, not only the quantity but also the quality of AB donations was improved.
The best predictor of the number of units collected was, in our study, the mobilizable circulating iron. Goodnough et al. 15 have also showed a significant correlation between MCI and the number of units collected. However, in their study, baseline Hct was the strongest predictor of the number of units collected. This was not the case in our study. In this study, the strongest predictor was MCI. This observation was true for the rHuEPO-treated groups as well as for the placebo group. This means that, in case of intensive phlebotomies, whether erythropoiesis is stimulated or not by exogenous erythropoietin, mobilisation of storage iron may be too slow or inefficient for the requirements of RBC production. The implication of this observation is that there is a need for another source of iron through oral or intravenous [22] [23] Moreover, in our study, patients unable to donate more than 3 units during the donation period were those with the lowest basal MCI, TI and SI. This would suggest that early iron supplementation would be possibly helpful during rHuEPO therapy in iron-deficient patients.
Despite the indirect proof of exogenous iron requirement during stimulation of erythropoiesis, the utility of iron suplementation for AB donation stimulated by rHuEPO remains controversial. 4, 10, [24] [25] [26] Through calculated evaluation of iron pools in the different compartments of the body and donated blood units, we were able to estimate the total amount of orally absorbed iron throughout the pre-surgery period. Despite some consumption of storage iron, as shown by a decrease of ferritin levels during the pre-surgery period, stimulated erythropoiesis depended largely on an external iron supply. SI estimation from serum ferritin levels may be a little underestimated during rHuEPO therapy because erythroid marrow expansion drives down the labile iron pool in macrophages and thereby decreases serum ferritin even when iron stores remain constant. 6 However, this was no longer the case at time of surgery because erythropoietic activity had virtually returned to normal. We found greatly increased iron absorption in the rHuEPO groups when compared to the placebo group.
With reference to an iron absorption of 1 mg/d in iron-replete normal individuals, iron absorption was more than doubled (2.2 mg/d) in the placebo group. In group 2, iron absorption was increased 15.5-fold compared to normal individuals and 7-fold compared to group 1, whereas in group 3 it increased 28.2-fold and 12.8-fold, respectively. Iron absorption was, thus, EPO dose-dependent. Our results show that increased erythropoietic activity, and not EPO levels per se, was responsible for enhanced iron absorption. Using a technique of radioiron absorption and incorporation into red cells, Skikne et al. 27 have demonstrated increased oral absorption of non-heme iron (3.5-9 fold) following administration fo rHuEPO Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to normal subjects. We demonstrated that this holds true with even stronger stimulation of erythropoiesis over a longer period of time. Thus, our study suggests that erythropoietic stimulation by rHuEPO could even be a much stronger stimulator of iron absorption than storage iron regulation. This huge iron absorption was only possible with oral iron supplementation and would not have been possible with mere dietary intake. RHuEPOinduced iron deficiency was not the driver of increased iron absorption, with ferritin levels remaining well within the normal ranges, but we cannot exclude that functional iron deficiency could be a mechanism contributing to rHuEPO-enhanced iron absorption since the correlation between iron absorption and TSAT was at the limit of significance. It has also been demonstrated that hepcidin, which has been shown to inhibit iron absorption and iron release by macrophages, is less produced when erythropoiesis is stimulated. 28 In conclusion, rHuEPO therapy was safe and effective, ensuring the success of the AB donation program. In addition to its well-known effect on the number of units collected, this study also demonstrates the higher quality of units donated under rHuEPO therapy. It appeared that mobilizable circulating iron was the best predictor of the number of collectable units, reflecting inadequate storage iron release and emphasizing the need for exogenous iron supplementation. Oral iron supplementation was proven to be useful as its absorption was strongly enhanced by the stimulated erythropoiesis induced by rHuEPO administration. Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Transfusion   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
